Related Experiment Video

Updated: Aug 11, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor

Hong-ying Zhen1, Yun-hong Huang, Yong-su Zhen

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. zhenys@public.bta.net.cn

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|February 25, 2006
PubMed
Abstract

Insights

Lidamycin (LDM) potently inhibits cancer cell growth by blocking basic fibroblast growth factor (bFGF) receptors and related signaling pathways. This mechanism suggests LDM

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Basic fibroblast growth factor (bFGF) signaling is crucial for cancer cell proliferation and survival.
  • Lidamycin (LDM) is an anti-cancer agent with a poorly understood mechanism of action.
  • Understanding LDM's molecular targets is essential for optimizing its therapeutic potential.

Purpose of the Study:

  • To elucidate the mechanism by which lidamycin (LDM) inhibits basic fibroblast growth factor (bFGF) signaling in cancer cells.
  • To investigate LDM's effects on bFGF receptor binding and downstream signal transduction pathways.
  • To compare the efficacy of LDM with adriamycin (ADR) in cancer cell lines.

Main Methods:

  • Cell viability was assessed using MTT assays.
  • Inhibition of bFGF binding to its receptor was measured via radioligand binding assays.
  • Intracellular calcium mobilization was monitored using Fura-3.
  • Western blotting was employed to analyze bFGF-receptor complex formation and protein kinase C (PKC) activity.

Main Results:

  • LDM exhibited potent, dose-dependent growth inhibition across multiple cancer cell lines, significantly exceeding ADR's efficacy (1000-fold greater potency).
  • LDM effectively blocked bFGF binding to its receptor with a low IC50 value (2.0 x 10^-4 nmol/L).
  • LDM inhibited bFGF-induced calcium influx and suppressed the activity of PKC isoenzymes activated by bFGF signaling.

Conclusions:

  • LDM's anti-cancer effects are mediated, at least in part, by inhibiting bFGF receptor-mediated signal transduction.
  • Blocking bFGF receptor activation represents a key mechanism of lidamycin's potent anti-proliferative activity in cancer cells.
  • Further research into LDM's targeted inhibition of growth factor signaling pathways may reveal new therapeutic strategies.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...